Research article

Sphingomyelin phosphodiesterase-1 (SMPD1) coding variants do not contribute to low levels of high-density lipoprotein cholesterol

Zari Dastani, Isabelle L Ruel, James C Engert, Jacques Genest Jr and Michel Marcil*

Address: From the Cardiovascular Research Laboratories, Division of Cardiology, McGill University Health Centre/Royal Victoria Hospital, Montréal, Québec H3A 1A1, Canada

Email: Zari Dastani - zari.dastani@mail.mcgill.ca; Isabelle L Ruel - isabelle.ruel@mcgill.ca; James C Engert - jamie.engert@mcgill.ca; Jacques Genest - jacques.genest@muhc.mcgill.ca; Michel Marcil* - michel.marcil@mcgill.ca

* Corresponding author

Abstract

Background: Niemann-Pick disease type A and B is caused by a deficiency of acid sphingomyelinase due to mutations in the sphingomyelin phosphodiesterase-1 (SMPD1) gene. In Niemann-Pick patients, SMPD1 gene defects are reported to be associated with a severe reduction in plasma high-density lipoprotein (HDL) cholesterol.

Methods: Two common coding polymorphisms in the SMPD1 gene, the G1522A (G508R) and a hexanucleotide repeat sequence within the signal peptide region, were investigated in 118 unrelated subjects of French Canadian descent with low plasma levels of HDL-cholesterol (< 5th percentile for age and gender-matched subjects). Control subjects (n = 230) had an HDL-cholesterol level > the 25th percentile.

Results: For G1522A the frequency of the G and A alleles were 75.2% and 24.8% respectively in controls, compared to 78.6% and 21.4% in subjects with low HDL-cholesterol (p = 0.317). The frequency of 6 and 7 hexanucleotide repeats was 46.2% and 46.6% respectively in controls, compared to 45.6% and 49.1% in subjects with low HDL-cholesterol (p = 0.619). Ten different haplotypes were observed in cases and controls. Overall haplotype frequencies in cases and controls were not significantly different.

Conclusion: These results suggest that the two common coding variants at the SMPD1 gene locus are not associated with low HDL-cholesterol levels in the French Canadian population.

Background

A low plasma level of high-density lipoprotein (HDL) cholesterol is defined as a cardiovascular risk factor and is part of the assessment of global cardiovascular risk stratification [1]. Therapeutic goals set for the prevention of cardiovascular disease include targets for low density lipoprotein (LDL) cholesterol, non-HDL-cholesterol [2], and the total cholesterol to HDL-cholesterol ratio [3]. However, a goal for an absolute HDL-cholesterol value is still a matter of controversy as the current therapeutic approaches are limited in their ability to raise HDL-cholesterol [4]. In the majority of cases, a low HDL-cholesterol is secondary to increased hepatic secretion of apolipoprotein B-containing lipoproteins and triglycer-
idelia defined as plasma triglycerides > 10 mmol/L, cel-

phospholipid or cholesterol efflux defect or previously known mutations in genes associated with HDL deficiency). The control group was of same origin and chosen based on HDL-cholesterol levels > 25th percentile, matched for age and gender. Demographic and clinical information, medications, blood pressure, and lipoprotein profiles were determined on all participating subjects. Hypertension was defined as a blood pressure ≥ 130/85 mmHg. Coronary artery disease (CAD) was present when angiographically documented or patient had a past history of acute myocardial infarction. Consent was obtained for the plasma sampling and DNA isolation. The research protocol was reviewed and approved by the Research Ethics Board of the McGill University Health Centre (REB No. BMA 05-006).

**Measurement of plasma lipids and lipoprotein**
The lipid lowering agents were withdrawn in all study subjects for at least four weeks before measurement of the lipid profile. Insulin and oral hypoglycemic agents were maintained in diabetic patients. Plasma was isolated in all study subjects, after a 12-hour fast, in EDTA-containing tubes. Lipids and lipoproteins were measured using standardized techniques and the LDL-cholesterol was calculated according to the Friedewald formula, unless triglyceride levels were > 4.5 mmol/L [12,13].

**DNA analysis**
DNA was isolated from the buffy coat obtained after centrifugation of whole blood. Two previously reported common polymorphisms of the SMPD1 gene in Niemann-Pick disease type A and B [14,15] were examined. The G→A substitution at position c.1522 located in exon 6 of the SMPD1 gene, predicting a substitution of arginine (R) for a glycine (G) at residue 508 (G508R) [rs1050239] was detected by polymerase chain reaction followed by digestion with the restriction enzyme Mspl (New England Biolabs, MA, USA). The hexanucleotide repeat polymorphism at the start position c.103 (genomic position: 6368507) [10] was located in exon 1 of the SMPD1 gene and detected using the sense primer 5’-GTCAGCCGACTACAGAGAAG-3’ and the antisense primer 5’-GGCATCTAGCAATCCATCA-CAATCCATCA-3’. The antisense primer was radiolabeled at the 5’ end with T4 polynucleotide kinase [32P]ATP (PerkinElmer, MA, USA) by standard procedures. Polymerase chain reaction products were resolved on a 6% polyacrylamide denaturing gel.

**Data analysis**
The data was analyzed by examining allele frequencies in subjects with low HDL-cholesterol versus controls. The DeFinetti program [16] was employed to test the deviation from Hardy-Weinberg equilibrium and also to compare the frequency of the SNPs between cases and controls. For the G1522A SNP, HDL-cholesterol levels were compared between homozygotes of the common

Methods

Subject characteristics
A total of 348 unrelated subjects of French Canadian origin (118 with low HDL-cholesterol levels and 230 control subjects) were examined at the McGill University Health Centre. Low HDL-cholesterol levels were defined as those less than the 5th percentile (age and gender-matched), based on the Lipid Research Clinics Population Studies Data Book [11]. Subjects with low HDL-cholesterol had no known cause of HDL deficiency (severe hypertriglyc-

Niemann-Pick disease type A and B is caused by a deficiency of the enzyme acid sphingomyelinase coded by SMPD1 gene. SMPD1 gene defects are reported to be associated with a severe reduction in plasma HDL-cholesterol [7]. In the search for genes causing disorders of HDL-cholesterol, we examined extended (3 or more generations) kindred of French Canadian descent to identify Mendelian traits. Using this approach, we have previously reported that compound heterozygosity in the SMPD1 gene is associated with decreased activity of acid sphingo-

...phosphoesterase domain. Although rare mutations in the SMPD1 gene can impair the function of acid sphingo-

The lipid lowering agents were withdrawn in all study subjects for at least four weeks before measurement of the lipid profile. Insulin and oral hypoglycemic agents were maintained in diabetic patients. Plasma was isolated in all study subjects, after a 12-hour fast, in EDTA-containing tubes. Lipids and lipoproteins were measured using standardized techniques and the LDL-cholesterol was calculated according to the Friedewald formula, unless triglyceride levels were > 4.5 mmol/L [12,13].

**DNA analysis**
DNA was isolated from the buffy coat obtained after centrifugation of whole blood. Two previously reported common polymorphisms of the SMPD1 gene in Niemann-Pick disease type A and B [14,15] were examined. The G→A substitution at position c.1522 located in exon 6 of the SMPD1 gene, predicting a substitution of arginine (R) for a glycine (G) at residue 508 (G508R) [rs1050239] was detected by polymerase chain reaction followed by digestion with the restriction enzyme Mspl (New England Biolabs, MA, USA). The hexanucleotide repeat polymorphism at the start position c.103 (genomic position: 6368507) [10] was located in exon 1 of the SMPD1 gene and detected using the sense primer 5’-GTCAGCCGACTACAGAGAAG-3’ and the antisense primer 5’-GGCATCTAGCAATCCATCA-CAATCCATCA-3’. The antisense primer was radiolabeled at the 5’ end with T4 polynucleotide kinase [32P]ATP (PerkinElmer, MA, USA) by standard procedures. Polymerase chain reaction products were resolved on a 6% polyacrylamide denaturing gel.

**Data analysis**
The data was analyzed by examining allele frequencies in subjects with low HDL-cholesterol versus controls. The DeFinetti program [16] was employed to test the deviation from Hardy-Weinberg equilibrium and also to compare the frequency of the SNPs between cases and controls. For the G1522A SNP, HDL-cholesterol levels were compared between homozygotes of the common
allele and both heterozygotes and homozygotes for the rare allele pooled together. Deviation from Hardy-Weinberg equilibrium for the hexanucleotide repeat polymorphism was tested by PEDSTATS version 0.6.5. The CLUMP program version 2.3 was used to assess the significance of the same marker between cases and controls, by using 1000 simulations in a Monte Carlo approach [17].

Haplotype frequencies (containing both polymorphisms) were estimated for cases and controls, using PHASE version 2.02 [18].

Power calculations using the Genetic Power Calculator [19] demonstrated that we would have > 80% power with our given sample size (controls = 230, cases = 118) to detect a SNP that accounts for 0.02 or more of the variance in HDL-cholesterol. This assumes that we are directly testing a causative variant with an allele frequency of 23% with a type I error rate $\alpha = 0.05$.

Statistical analyses were performed with the SAS package version 8 (SAS Institute Inc., NC, USA) and SigmaStat version 2.0 (Jandel Corporation, San Rafael, CA, USA). A $\chi^2$ analysis (GraphPad InStat, CA, USA) was performed with respect to allele frequencies in each of the HDL-cholesterol groups. Age, body mass index (BMI), and all lipid parameters in both groups were treated as continuous variables. Comparisons were made through generalized linear model procedures (Proc GLM) followed by Duncan’s post hoc test. All $p$-values < 0.05 were considered significant.

**Results**

We analyzed a total of 348 subjects from a pool of control subjects and patients with premature CAD. The selection criterion was an HDL-cholesterol < 5th percentile for cases ($n = 118$), and an HDL-cholesterol > 25th percentile for controls ($n = 230$). Mean ages were 50 ± 10 and 50 ± 9 years for control and case groups, respectively. Additional demographic and biochemical characteristics are shown in Table 1. Subjects with a low HDL-cholesterol had a higher BMI, were more likely to have type II diabetes, hypertension, CAD and a family history of CAD. These correlates of low HDL-cholesterol have been previously well established [20]. The low HDL-cholesterol group had an HDL-cholesterol of 0.67 ± 0.13 mmol/L and the control group had a mean HDL-cholesterol of 1.35 ± 0.33 ($p < 0.001$). Plasma triglyceride levels were higher in the low HDL-cholesterol group than in the controls (3.95 ± 3.35 mmol/L vs. 1.63 ± 0.89 mmol/L, $p < 0.001$).

We examined two polymorphisms at the SMPD1 gene locus: G1522A (G508R) and a hexanucleotide repeat sequence CTGG (TC)(GT). From our 348 subjects analyzed, 230 controls and 117 cases were successfully genotyped. The prevalence of the G508R variant in cases and controls is shown in Table 2. The presence of the G allele was seen in 75.2% of controls and 78.6% of subjects with low HDL-cholesterol (OR = 0.82; $p = 0.317$). We also separately analyzed the association of this variant between patients with and without CAD and no significant difference was confirmed ($p = 0.06$, data not shown). Genotype frequencies for the GG, GA and AA classes did not differ between subjects with low HDL-cholesterol and controls (Table 2). We found significant associations between the genotypic classes with familial history of CAD ($p = 0.0003$), total plasma cholesterol, plasma LDL-cholesterol, between subjects with the GG genotype and subjects with either the AG or AA genotypes in cases and controls (Table 3).

We found significant associations between the genotypic classes with familial history of CAD ($p = 0.0003$), total plasma cholesterol ($p = 0.03$) and LDL-cholesterol ($p = 0.02$) in controls. In addition, we found significant associations between the genotypic classes with total cholesterol ($p = 0.009$) in the low HDL-

| Table 1: Baseline characteristics of low HDL-C and control subjects |
|---------------------------------------------------------------|
| Control subjects ($n = 230$) | Low HDL-C subjects ($n = 118$) | $t$ test $p^*$ |
| Age (y) | 50 ± 9 | 50 ± 10 | 0.93 |
| Gender (M/F) | 150/80 | 85/33 | 0.20 |
| BMI (kg/m²) | 26.3 ± 4.5 | 28.1 ± 4.9 | 0.001 |
| DM (%) | 10.4 | 21.2 | 0.01 |
| HTN (%) | 20.4 | 45.8 | $<0.001$ |
| CAD (%) | 49.8 | 72.3 | $<0.001$ |
| FH of CAD (%) | 61.3 | 72.6 | 0.04 |
| TG (mmol/L) | 1.63 ± 0.89 | 3.95 ± 3.35 | $<0.001$ |
| T Chol (mmol/L) | 5.73 ± 1.41 | 5.98 ± 2.20 | 0.26 |
| HDL-C (mmol/L) | 1.35 ± 0.33 | 0.67 ± 0.13 | $<0.001$ |
| LDL-C (mmol/L) | 3.70 ± 1.33 | 3.50 ± 1.61 | 0.27 |

BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; CAD, coronary artery disease; FH, familial history; TG, plasma triglycerides; T Chol, total plasma cholesterol; HDL-C, plasma high-density lipoprotein cholesterol; LDL-C, plasma low-density cholesterol.

* significant $p$-value bolded.
cholesterol subjects. We did not find any significant difference in the prevalence of the GG or AG + AA genotypes with the presence of diabetes. The analysis was also carried out separately between each genotypic class (GG, AG and AA), and the results were similar as those presented in Table 3.

The second polymorphism consisted of a unique hexanucleotide sequence CTGG(TC)(GT) located within the signal peptide region of the acid sphingomyelinase (corresponding to the hydrophobic sequence LVLALALALALA). The genotype distribution of the hexamer polymorphism was examined and the most frequent allele was the 6 and 7 repeats (respectively 46% and 47% of the control group) (Table 4). We identified 9 genotypes in our study population with the most prevalent being 6/6, 6/7, 7/7 and 6/6. There was no significant difference in the genotype or allele frequencies between low HDL-cholesterol subjects and controls. We used the CLUMP program to confirm these results with a \( p \)-value of 0.6 after a 1000-simulation analysis. We examined the most frequent genotypes with respect to age, gender, BMI, diabetes mellitus, CAD, family history of CAD, triglycerides, total cholesterol and LDL-cholesterol levels and we found significant differences between the subgroups of subjects with 6/6, 6/7, 7/7 for hypertension \( (p = 0.04) \) and triglycerides \( (p = 0.005) \) in low HDL-cholesterol subjects only (Table 5).

We used the PHASE program to reconstruct haplotypes in cases and controls. Substantial linkage disequilibrium was observed as the A allele of G1522A was seen almost exclusively with the hexanucleotide repeat of "6" (Table 6). Overall haplotype frequencies between cases and controls were not significantly different \( (p = 0.5) \) (Table 6).

### Discussion

The present report suggests that common genetic variability at the SMPD1 gene locus does not contribute significantly to HDL-cholesterol levels in a French Canadian population. Rare mutations at the SMPD1 gene can cause

---

### Table 2: Genotype distribution and allele frequency of the G1522A variant in the SMPD1 gene in control and low HDL-cholesterol subjects.

| Genotype or allele | Control subjects (n) | Low HDL-cholesterol subjects (n) | \( \chi^2 \), two-sided \( p \)-value and O.R. |
|-------------------|----------------------|----------------------------------|-----------------------------------------------|
| GG                | 56.1% (129)          | 64.1% (75)                      | 0.152†                                        |
| AG                | 38.3% (88)           | 29.1% (34)                      | 0.72 (0.45–1.13)‡                             |
| AA                | 5.6% (13)            | 6.8% (8)                        |                                               |
| G                 | 75.2%                | 78.6%                           | 0.317                                         |
| A                 | 24.8%                | 21.4%                           | 0.82 (0.57–1.20)‡                             |

O.R., odd ratio
† AG and AA genotypes where pooled for statistical analysis
‡ 95% confidence interval for O.R.

### Table 3: Comparison of biochemical data of the low HDL-C and control subjects between different groups of G1522A genotypes.

|                      | Control subjects | t test p * | Low HDL-C subjects | t test p * |
|----------------------|------------------|------------|--------------------|------------|
| GG                   | 129              |            | 75                 |            |
| AG + AA              | 101              |            | 42                 |            |
| Age (y)              | 50 ± 10          | 0.5        | 49 ± 9             | 0.4        |
| Gender (M/F)         | 81/48            | 0.3        | 52/23              | 0.4        |
| BMI (kg/m²)          | 26.4 ± 4.6       | 0.9        | 28.3 ± 5.2         | 0.5        |
| DM (%)               | 10.5             | 0.9        | 20.3               | 0.9        |
| HTN (%)              | 19.3             | 0.5        | 51.3               | 0.06       |
| CAD (%)              | 45.9             | 0.1        | 75.4               | 0.3        |
| FH of CAD (%)        | 51.7             | 0.0003     | 75.0               | 0.4        |
| TG (mmol/L)          | 1.60 ± 0.89      | 0.4        | 4.34 ± 3.89        | 0.07       |
| T Chol (mmol/L)      | 5.55 ± 1.19      | 0.03       | 6.33 ± 2.39        | 0.009      |
| HDL-C (mmol/L)       | 1.34 ± 0.31      | 0.8        | 0.67 ± 0.13        | 0.9        |
| LDL-C (mmol/L)       | 3.51 ± 1.10      | 0.02       | 3.71 ± 1.74        | 0.09       |

BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; CAD, coronary artery disease; FH, familial history; TG, plasma triglycerides; T Chol, total plasma cholesterol; HDL-C, plasma high-density lipoprotein cholesterol; LDL-C, plasma low-density cholesterol.

* significant \( p \)-value bolded.
Niemann-Pick disease type A or B, which can differ in degrees of neurological impairment. Mutations for both types A and B are distributed throughout the \textit{SMPD1} gene and the structure-function relationship between mutations and disease states is not fully understood. We and others have previously reported that patients with Niemann-Pick disease type A/B have low plasma levels of HDL-cholesterol [7,8,22]. More recently, we have shown that cellular cholesterol processing is abnormal in fibroblasts with \textit{SMPD1} mutations [9]. Despite an abnormal lysosomal transport of cholesterol and sphingomyelin, cellular cholesterol efflux onto apolipoprotein A-I does not appear to be the rate-limiting step in generating nascent HDL particles. Instead, our data suggests that abnormal composition of nascent HDL particles leads to abnormal LCAT activity and decreased cholesterol esterification when the protein product of the \textit{SMPD1} gene, acid sphingomyelinase, is defective [9]. It has been previously reported that reconstituted HDL particles using proteoliposomes with an increasing ratio of sphingomyelin to phosphatidylcholine

| Genotype or allele | Control subjects (%) | Low HDL-C subjects (%) | p       |
|--------------------|----------------------|------------------------|---------|
| 5/5                | 0.4                  | 0                      | 0.527   |
| 5/6                | 6.3                  | 2.6                    |         |
| 5/7                | 5.4                  | 7.0                    |         |
| 6/6                | 20.3                 | 25.5                   |         |
| 6/7                | 45.6                 | 37.7                   |         |
| 7/7                | 20.3                 | 26.3                   |         |
| 7/8                | 0.4                  | 0                      |         |
| 7/9                | 0.9                  | 0.9                    |         |
| 7/10               | 0.4                  | 0                      |         |
| 5                  | 6.3                  | 4.8                    | 0.619   |
| 6                  | 46.2                 | 45.6                   |         |
| 7                  | 46.6                 | 49.1                   |         |
| 8                  | 0.2                  | 0                      |         |
| 9                  | 0.5                  | 0.5                    |         |
| 10                 | 0.2                  | 0                      |         |

Table 4: Genotype distribution and allele frequency of the hexanucleotide repeat polymorphism in the \textit{SMPD1} gene in low HDL-C and control subjects.

| Genotype or allele | Control subjects (%) | Low HDL-C subjects (%) | p       |
|--------------------|----------------------|------------------------|---------|
| 5/5                | 0.4                  | 0                      | 0.527   |
| 5/6                | 6.3                  | 2.6                    |         |
| 5/7                | 5.4                  | 7.0                    |         |
| 6/6                | 20.3                 | 25.5                   |         |
| 6/7                | 45.6                 | 37.7                   |         |
| 7/7                | 20.3                 | 26.3                   |         |
| 7/8                | 0.4                  | 0                      |         |
| 7/9                | 0.9                  | 0.9                    |         |
| 7/10               | 0.4                  | 0                      |         |
| 5                  | 6.3                  | 4.8                    | 0.619   |
| 6                  | 46.2                 | 45.6                   |         |
| 7                  | 46.6                 | 49.1                   |         |
| 8                  | 0.2                  | 0                      |         |
| 9                  | 0.5                  | 0.5                    |         |
| 10                 | 0.2                  | 0                      |         |

Table 5: Comparison of biochemical data of the low HDL-C and control subjects between the most prevalent genotypes of the hexanucleotide repeat polymorphism in the \textit{SMPD1} gene.

| Genotype or allele | Control subjects (\(n = 230\)) t test p | Low HDL-C subjects (\(n = 118\)) t test p* |
|--------------------|------------------------------------------|---------------------------------------|
| 5/5                |                                          |                                       |
| 6/6                | 6/7                                     | 7/7                                  | 6/6 | 6/7 | 7/7 |
| n                  | 45                                      | 101                                   | 45  | 29  | 43  | 30  |
| Age (y)            | 50 ± 8                                  | 50 ± 9                                | 49 ± 9 | 0.79 | 48 ± 10 | 51 ± 10 | 49 ± 10 | 0.51 |
| Gender (M/F)       | 30/15                                   | 68/33                                 | 29/16 | 0.94 | 22/7  | 29/14  | 20/10  | 0.69 |
| BMI (kg/m²)        | 26.1 ± 5.1                              | 26.4 ± 4.0                            | 26.0 ± 4.1 | 0.86 | 27.9 ± 4.2 | 27.8 ± 5.1 | 29.2 ± 5.6 | 0.45 |
| DM (%)             | 15.0                                    | 55.0                                  | 30.0  | 0.57 | 19.0  | 42.9   | 38.1   | 0.47 |
| HTN (%)            | 23.1                                    | 61.5                                  | 15.4  | 0.35 | 22.2  | 35.6   | 42.2    | 0.04 |
| CAD (%)            | 26.1                                    | 51.1                                  | 22.8  | 0.77 | 23.9  | 45.1   | 31.0   | 0.16 |
| FH of CAD (%)      | 28.3                                    | 53.3                                  | 18.3  | 0.05 | 23.6  | 43.1   | 33.3   | 0.15 |
| TG (mmol/L)        | 1.60 ± 0.68                             | 1.56 ± 0.85                           | 1.68 ± 0.88 | 0.71 | 2.73 ± 1.38 | 4.94 ± 3.65 | 3.57 ± 2.58 | 0.005 |
| T Chol (mmol/L)    | 6.09 ± 1.45                             | 5.61 ± 1.52                           | 5.82 ± 1.32 | 0.19 | 5.56 ± 2.21 | 6.12 ± 1.77 | 6.03 ± 2.06 | 0.48 |
| HDL-C (mmol/L)     | 1.36 ± 0.34                             | 1.33 ± 0.31                           | 1.31 ± 0.28 | 0.80 | 0.66 ± 0.11 | 0.67 ± 0.13 | 0.69 ± 0.10 | 0.55 |
| LDL-C (mmol/L)     | 3.96 ± 1.37                             | 3.60 ± 1.34                           | 3.79 ± 1.39 | 0.32 | 3.60 ± 2.08 | 3.38 ± 1.34 | 3.68 ± 1.62 | 0.74 |

BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; CAD, coronary artery disease; FH, familial history; TG, plasma triglycerides; T Chol, plasma cholesterol; HDL-C, plasma high-density lipoprotein cholesterol; LDL-C, plasma low density lipoprotein cholesterol.

*significantly different from genotype 6/6.

* significant p value bolded.
inhibits LCAT activity and cholesteryl ester formation [23-25]. This leads to an inability of HDL particles to mature into spherical HDL$_3$ particles. In turn, current evidence points to an increased catabolism of these nascent, cholesteryl ester-poor HDL particles by the kidney [26].

In a previous report, we have shown that rare mutations of the SMPD1 gene leads to reduced activity of acid sphingomyelinase and is associated with a low HDL-cholesterol. In addition, the mutations segregate within families with a gene dosage effect. This gene-dosage effect was shown in HDL-cholesterol levels in homozygotes and compound heterozygotes [8]. Here, we have found that the prevalence of the G1522A substitution (G508R) was not significantly different in subjects with a low HDL-cholesterol, compared with controls. We used the PolyPhen program [27] to determine the predicted impact of individual variants on SMPD1 function and this variant was predicted to be benign.

Moreover, the presence of the 6 and 7 hexanucleotide repeats as well as the 10 different haplotypes in cases and controls were not significantly different. In a previous report, the 5 separate alleles, corresponding to 9, 7, 6, 5 and 4 hexanucleotide repeats were unrelated to Niemann-Pick disease [15]. Corresponding allele frequencies of 0.5%, 12.4%, 50.4%, 34.9% and 1.8% were found in that study, generating 9 different genotypes [15].

Some significant associations were found between SMPD1 genotypic classes and characteristics of the cases and control subjects. For example, in the control group, carriers of the 1522A had a significant increase in family history of CAD, plasma LDL-cholesterol and total cholesterol levels. However, the 1522A allele was associated with lower total plasma cholesterol concentrations in the cases. Given the lack of consistency of these results between the control and low HDL-cholesterol groups, and the relative statistical weakness of these associations (not significant or only marginally significant when Bonferroni corrections are applied for multiple testing), the clinical relevance of these findings is uncertain and are probably the result of multiple statistical tests.

This study is limited by the relatively small number of subjects (n = 348). However, we did have greater than 80% power to detect a genetic variant that accounts for as little as 2% of the variance of HDL-cholesterol. In addition, we used arbitrary cut-points of an HDL-cholesterol < 5th percentile and > 25th percentile for cases and controls, respectively. These data should still be confirmed in a large-scale study.

**Conclusion**

Our data suggest that while rare mutations at the SMPD1 locus can cause Niemann-Pick disease types A and B and the concomitant low HDL-cholesterol, the two common coding non-synonymous variants that we examined at this locus do not appear to influence HDL-cholesterol levels to any great extent. Forty-five mutations in SMPD1 gene causing different forms of Niemann-Pick disease type A and B have been described [28]. Since the incidence of Niemann-Pick disease type B is difficult to estimate due to the lack of enzyme testing in clinic, variability in symptoms and the lack of knowledge of Niemann-Pick disease type B by treating physicians, many patients remain undiagnosed [28]. It remains to be determined if variations in the SMPD1 gene, affecting the activity of acid sphingomyelinase, might contribute to the modulation of HDL-cholesterol levels in the general population. This study did not examine rare mutations and thus carrier status for Niemann-Pick disease type B was not ruled out in either group. However, Niemann-Pick disease type B should not be common enough to influence our findings.

**Abbreviations**

BMI, body mass index; CAD, coronary artery disease; HDL, high-density lipoprotein; LCAT, lecithin:cholesterol acyltransferase; LDL, low density lipoprotein; SMPD1, sphingomyelin phosphodiesterase-1.

**Competing interests**

The author(s) declare that they have no competing interests.
Authors’ contributions
ZD and JCE carried out the analysis of data, participated in the design of the study and the writing of the paper; ILR and ZD carried out the genotyping of the samples; ILR participated in the data analysis and the writing of the paper; MM participated in the patient collection and characterization, the design of the study, the genotyping of the samples, the data analysis and the writing of the paper; JG carried out the clinical examination and collection of the patients, the design of the study and participated in the writing of the paper. All the authors read and approved the final manuscript.

Acknowledgements
This study was supported by the Canadian Institute of Health Research [CIHR grant MOP-62834 (JG) and CIHR grant MOP-74703 (MM)] and the Heart and Stroke Foundation of Québec (MM). MM and J. Engert are research scholars from the Fonds de la Recherche en Santé du Québec. JG holds the McGill University-Novartis Chair in Cardiology. The authors thank their research nurses, Mrs. Colette Rondeau and Natalie Bellavance, for their work with the individuals who participated in this study, and Ms. Carole Dangioisse, summer student, for her technical assistance. The authors would like to thank Ron Do, graduate student, for helpful discussions.

References
1. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr., Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr., Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004, 44:720-732.
2. NCEP: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III), JAMA 2001, 285:2486-2497.
3. McPherson R, Frohlich J, Fodor G, Genest J, Society CC: Canadian Cardiovascular Society position statement—recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006, 22:913-927.
4. Genest J, Pedersen TR: Prevention of cardiovascular ischemic events: high-risk and secondary prevention. Circulation 2003, 107:2059-2065.
5. Genest J Jr., Bard JM, Fruchart JC, Ordovas JM, Schaefer EJ: Familial hypoalphapolipoproteinemia in premature coronary artery disease. Arteroscler Thromb Vasc Biol 1993, 13:1728-1737.
6. Dastani Z, Engert JC, Genest J, Marcil M: Genetics of high-density lipoproteins. Curr Opin Cardiol 2006, 21:329-335.
7. McGovern MM, Pohl-Worgall T, Deckelbaum RJ, Simpson W, Mendelson D, Desnick RJ, Schuchman EH, Wasserstein MP: Lipid abnormalities in children with types A and B Niemann-Pick disease. J Pediatr 2004, 145:77-81.
8. Lee CY, Krimbou L, Vincent J, Bernard C, Larramee P, Genest J Jr., Marcil M: Compound heterozygosity at the sphingomyelin phosphodiesterase-1 (SMPD1) gene is associated with low HDL cholesterol. Hum Genet 2003, 112:552-562.
9. Lee CY, Lesimple A, Denis M, Vincent J, Larsen A, Mamer O, Krimbou L, Genest J, Marcil M: Increased sphingomyelin content impairs HDL biogenesis and maturation in human Niemann-Pick disease type B. J Lipid Res 2006, 47:622-632.
10. Karolchik D, Baertsch R, Diekhans M, Furey TS, Hinrichs A, Lu YT, Roskin KM, Schwartz M, Sugnet CW, Thomas DJ, Weber RJ, Haussler D, Kent WJ: The UCSC Genome Browser Database. Nucleic Acids Res 2003, 31:S1-S14.
11. Health NI: Lipid Research Clinics Population Studies Data- book. Volume I. Washington DC, Department of Health and Human Services, Public Health Service; 1980:28-41.
12. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
13. Alenezi MY, Marcil M, Blank D, Sherman M, Genest J Jr.: Is the decreased high-density lipoprotein cholesterol in the metabolic syndrome due to cellular lipid efflux defect? J Clin Endocrinol Metab 2004, 89:761-764.
14. Schuchman EH, Levrán O, Suchi M, Desnick RJ: An Mspl polymorphism in the human acid sphingomyelinase gene (SMPD1). Nucleic Acids Res 1991, 19:3160.
15. Wan Q, Schuchman EH: A novel polymorphism in the human acid sphingomyelinase gene due to size variation of the signal peptide region. Biochim Biophys Acta 1995, 1270:207-210.
16. Sorensen TM, TF W: DeFinetti program. 2004.
17. Sham PC, Curtis D: Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995, 59:97-105.
18. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Ann J Hum Genet 2001, 68:978-989.
19. Purcell S: Genetic Power Calculator. 2001.
20. Bonora E: The metabolic syndrome and cardiovascular disease. Ann Med 2006, 38:64-80.
21. National Center for Biotechnology Information. 2006, SNP database # rs1050239, NCBI assay ID # ss2405827 from PERLEGEN for European panel.
22. Viana MB, Giugliani R, Leite VH, Barth ML, Lekhwani C, Slade CM, Fensom A: Very low levels of high density lipoprotein cholesterol in four sibs of a family with non-atherosclerotic Niemann-Pick disease and sea-blue histiocytosis. J Med Genet 1990, 27:499-504.
23. Subbaiah PV, Liu M: Role of sphingomyelin in the regulation of cholesterol esterification in the plasma lipoproteins. Inhibition of lecinthin-cholesterol acyltransferase reaction. J Biol Chem 1993, 268:20156-20163.
24. Rye KA, Hime NJ, Barter PJ: The influence of sphingomyelin on the structure and function of reconstituted high density lipoproteins. J Biol Chem 1996, 271:4243-4250.
25. Bolin DJ, Jonas A: Sphingomyelin inhibits the lecinthin-cholesterol acyltransferase reaction with reconstituted high density lipoproteins by decreasing enzyme binding. J Biol Chem 1996, 271:19152-19158.
26. Rye KA, Barter PJ: Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arteroscler Thromb Vasc Biol 2004, 24:421-428.
27. PolyPhen: prediction of functional effect of human nsSNPs. 2007.
28. Simanor CM, Desnick RJ, McGovern MM, Wasserstein MP, Schuchman EH: The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations. Am J Hum Genet 2002, 71:1413-1419.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2350/8/79/prepub